Edward S. Kim, MD, FACP, MBA

02/04/2022

Drivers of Prescribing Long-Acting Injectable Antipsychotics to Patients with Schizophrenia

Long-acting injectable (LAI) antipsychotics are recommended by clinical guidelines for patients with schizophrenia who struggle with adherence and/or recurrent relapses. However, LAI util...

Alexander Keenan , MA, MS, MD;

Dee Lin , PharmD, MS;

Jason Shepherd , BA;

Hollie Bailey , BSc;

Jack Wright ;

Carmella Benson , MSc, MS, MSHP;

Katy Bacon ;

Edward S. Kim , MD, FACP, MBA;

10/08/2020

Combination Therapies: Your Questions Answered

Edward S. Kim , MD, FACP, MBA;

Sarah Nadia Joseph , MD;

William S. Rilling , MD, FSIR;

Robert J. Lewandowski , MD, FSIR;

02/05/2022

A Systematic Literature Review of Schizophrenia Clinical Practice Guidelines: Recommendations on use of Long-acting Injectable Anti-psychotic Medications

Background and Objectives: Many clinical practice guidelines (CPGs) on the treatment of schizophrenia have been updated. Aiming to review current CPGs, focusing specifically on long-actin...

Kruti Joshi , MPH, MD;

Edward S. Kim , MD, FACP, MBA;

Christoph U. Correll , MD;

Charmi Patel , BS , RN, BSN, MPH;

Amber Martin , BS;

Rebecca Goulding , PhD;

Jennifer Kern Sliwa , PharmD, BCPP;

Emma Schiller , BA;

Carmella Benson , MSc, MS, MSHP;

10/08/2020

Advances in the Multidisciplinary Medical Management of Hepatocellular Carcinoma

Ripal Gandhi, MD, Michael Morse, MD, Edward Kim, MD, Maria Hernandez, MD, and Ramon Jimenez, MD discuss the current treatment paradigm for HCC.

Ripal T. Gandhi , MD, FSIR, FSVM;

Michael Morse , MD;

Maria Hernandez , MD;

Edward S. Kim , MD, FACP, MBA;

Ramon Jimenez , MD;

02/16/2022

Risk of Subsequent Relapses and Corresponding Healthcare Costs Among Recently-Relapsed Medicaid Patients With Schizophrenia

BACKGROUND: Schizophrenia relapses can cause a significant increase in healthcare resource utilization and costs. However, the risk of relapse may be different between patients initiated ...

Edward S. Kim , MD, FACP, MBA;

Patrick Lefebvre , MA;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

Bruno Emond , MA;

Charmi Patel , BS , RN, BSN, MPH;

Laura Morrison , MPH;

Maria-Helene Lafeuille , MA;

11/22/2019

Dose Matters

Nora Tabori, MD, Edward Kim, MD, and Riad Salem, MD present current thoughts on Y-90 dosimetry based on the EPOCH trial.

Edward S. Kim , MD, FACP, MBA;

Nora Tabori , MD;

Riad Salem , MD, MBA;

02/16/2022

Defining “Adequately Treated”: Characteristics of Patients With Schizophrenia Successfully Transitioned From Paliperidone Palmitate Once Monthly to Paliperidone Palmitate Once-Every-3-Months

Objective: To identify patient characteristics associated with successful transition to once-every-3-months paliperidone palmitate (PP3M).

Edward S. Kim , MD, FACP, MBA;

Amy O'Donnell , MD, JD, BS;

Sanjai Rao , MD;

Ibrahim Turkoz , PhD;

Srihari Gopal , MD;

11/22/2019

Relationship Between Improved Caregiver Burden and Associated Clinical Improvement in Schizophrenia Patients Treated With Paliperidone Palmitate

Objective: Burden is significant for caregivers of patients with schizophrenia. Little is known about the relationship between changes in patient illness severity and functioning and chan...

Kristy Tardieu , BSN, MBA;

Jagadish Gogate , PhD;

Branislav Mancevski , MD;

Edward S. Kim , MD, FACP, MBA;

03/01/2019

A Phase 3 Non-Inferiority Study Comparing Paliperidone Palmitate 1-Month vs 3-Month Long-Acting Injectables for Negative Symptom Improvement in Schizophrenia

Background: Negative symptoms of schizophrenia are predictors of long-term disability. Paliperidone palmitate 3-month formulation (PP3M) provides a sustained release of paliperidone, perm...

Edward S. Kim , MD, FACP, MBA;

Arun K. Singh , MD, PhD, MCh, MNAMS;

Katalin Pungor , PhD;

Maju Mathews , MD;

Jagadish Gogate , PhD;

Srihari Gopal , MD;

03/01/2019